Inovio Pharmaceuticals, Inc.
NASDAQ:INOBiotechnology
-$0.01 today
- Market cap
- $116.77M
- Beta
- 1.49
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$0.12
Volume 11.56M
Average 2.73M
INO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Inovio Pharmaceuticals, Inc.NASDAQ: INO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $19.68M (cash outflow) fell 0.1% year over year, ahead of the -12.0% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -32.8% a year.
Context
- Net income amounted to 130000.0% of revenue in FY2025, up 80745.7 pp from a year earlier.
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$40.79M (-52.0%) for the fiscal year ending Dec 2026, a slowdown from the -20.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$19.68M-622.8% QoQ
- Last fiscal yearDec 2025
- -$84.95M-20.8% YoY
- LTMMar 2026
- -$84.93M-12.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -0.1% | -9.1% | -9.1 pp |
| 1 year | -20.8% | -52.0% | -31.2 pp |
| 3-year CAGR | -32.8% | -81.7% | -48.9 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (84.95M) USD
- Year-over-year change
- +20.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (84.95M) | +20.8% |
| FY2024 | 2024-12-31 | (107.25M) | +20.6% |
| FY2023 | 2023-12-31 | (135.12M) | +51.7% |
| FY2022 | 2022-12-31 | (279.82M) | +7.9% |
| FY2021 | 2021-12-31 | (303.66M) | — |
Net Income vs competitors
How INO compares with its peers on the latest reported figures
- INO's LTM Mar 2026 net income of $84.93M is the 5th largest of the 10 companies compared; the peer median is $70.49M.
- Its year-over-year change of -12.0% is the 6th highest of 10, against a peer median of -2.6%.
- Over three fiscal years its annual growth of -32.8% compares with a peer median of +1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $129.91M | -26.1% | -21.5% | 2056.8% | |
| LTM Mar 2026 | $125.39M | +1.6% | +2.3% | 680.8% | |
| LTM Mar 2026 | $113.28M | -2.6% | +41.5% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $106.93M | +82.4% | — | 892.4% |
| LTM Mar 2026 | $84.93M | -12.0% | -32.8% | — | |
| LTM Mar 2026 | $70.49M | -17.9% | -7.5% | 468.7% | |
| LTM Mar 2026 | $62.51M | +132.2% | +0.2% | 50.5% | |
| LTM Mar 2026 | $46.9M | -164.3% | — | 4088.8% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $21.54M | -14.9% | +3.3% | — |
| LTM Mar 2026 | $15.24M | +121.8% | — | 27.8% | |
| Peer median (excluding INO) | $70.49M | -2.6% | +1.3% | 680.8% | |
Competitors are the stored peer set for INO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (303.66M) | (279.82M) | (135.12M) | (107.25M) | (84.95M) |
| Depreciation & Amortization | 4.73M | 5.5M | 3.5M | 3.13M | 2.99M |
| Deferred Income Tax | 0 | 4.03M | (32.05K) | 0 | 0 |
| Stock-Based Compensation | 26.34M | 22.56M | 11.07M | 6.6M | 3.76M |
| Change in Working Capital | 50.35M | 19.83M | (10.26M) | (2.66M) | (9.22M) |
| Accounts Receivables | 11.03M | (3.71M) | 9.33M | 1.21M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 26.14M | 32.61M | (45.99M) | (3.37M) | (6.42M) |
| Other Working Capital | 13.18M | (9.07M) | 26.4M | (504.04K) | (2.8M) |
| Other Non-Cash Items | 6.53M | 11.69M | 6.47M | (3.88M) | (1.21M) |
| Operating Cash Flow | (215.71M) | (216.22M) | (124.37M) | (104.08M) | (88.63M) |
| Capital Expenditures | (1.23M) | (969.15K) | (320.9K) | (487.83K) | (285.7K) |
| Acquisitions (Net) | 0 | (2M) | 6.22M | 0 | 0 |
| Purchases of Investments | (348.95M) | (248.53M) | (203.48M) | (54.14M) | (4.95M) |
| Sales of Investments | 174.84M | 361.08M | 284.93M | 158.64M | 19.27M |
| Other Investing Activities | 0 | 0 | 0 | 59.32K | 0 |
| Investing Cash Flow | (175.34M) | 109.59M | 87.36M | 104.07M | 14.04M |
| Debt Repayment | 0 | 0 | 0 | (16.42M) | 0 |
| Common Stock Issued | 209.44M | 82.96M | 5.46M | 68.31M | 53.16M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.06M | (1.11M) | (466.65K) | (420.8K) | (110.78K) |
| Financing Cash Flow | 211.5M | 81.84M | 5M | 51.48M | 53.05M |
| Effect of Forex Changes | (30.13K) | (25.56K) | (3.92K) | 32.4K | 0 |
| Net Change in Cash | (179.58M) | (24.81M) | (32.02M) | 51.5M | (21.54M) |
| Free Cash Flow | (216.94M) | (217.18M) | (124.69M) | (104.56M) | (88.92M) |
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
Intrinsic Alpha fair value
Locked
Current Price
$1.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.